$TPST
Tempest Therapeutics, Inc.

2016 Q3 Form 10-Q Financial Statement

#000154422716000013 Filed on August 04, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q2
Revenue $197.0K $189.0K $30.00K
YoY Change 162.67% 530.0%
Cost Of Revenue $1.559M $1.233M $116.0K
YoY Change 65.85% 962.93%
Gross Profit -$1.362M -$1.044M -$86.00K
YoY Change 57.46% 1113.95%
Gross Profit Margin -691.37% -552.38% -286.67%
Selling, General & Admin $12.61M $11.21M $13.07M
YoY Change -2.3% -14.21% 158.19%
% of Gross Profit
Research & Development $4.990M $5.987M $4.021M
YoY Change 24.81% 48.89% -11.31%
% of Gross Profit
Depreciation & Amortization $600.0K $600.0K $200.0K
YoY Change 100.0% 200.0% 100.0%
% of Gross Profit
Operating Expenses $19.16M $18.43M $17.20M
YoY Change 7.36% 7.13% 79.3%
Operating Profit -$18.96M -$18.24M -$17.17M
YoY Change 6.71% 6.21% 78.99%
Interest Expense -$200.0K -$260.0K -$290.0K
YoY Change 11.11% -10.34% -9.38%
% of Operating Profit
Other Income/Expense, Net -$33.00K -$22.00K -$28.00K
YoY Change -232.0% -21.43% -216.67%
Pretax Income -$19.20M -$18.52M -$17.49M
YoY Change 7.13% 5.88% 76.85%
Income Tax $92.00K $50.00K $0.00
% Of Pretax Income
Net Earnings -$19.29M -$18.57M -$17.49M
YoY Change 7.64% 6.16% 76.79%
Net Earnings / Revenue -9792.39% -9824.34% -58300.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$120.60 -$142.80 -$145.80
COMMON SHARES
Basic Shares Outstanding 35.56M shares 27.33M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $131.0M $147.7M $155.6M
YoY Change -7.55% -5.08% 91.15%
Cash & Equivalents $50.48M $95.89M $70.24M
Short-Term Investments $80.50M $51.80M $85.40M
Other Short-Term Assets $2.500M $2.500M $3.500M
YoY Change -30.56% -28.57% 191.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $133.5M $150.1M $159.2M
YoY Change -8.17% -5.69% 92.69%
LONG-TERM ASSETS
Property, Plant & Equipment $8.047M $8.149M $4.208M
YoY Change 19.8% 93.65% 121.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $435.0K $557.0K
YoY Change 80.5% -49.36%
Other Assets $23.00K $23.00K $0.00
YoY Change -100.0%
Total Long-Term Assets $8.944M $8.611M $5.292M
YoY Change 19.49% 62.72% 65.38%
TOTAL ASSETS
Total Short-Term Assets $133.5M $150.1M $159.2M
Total Long-Term Assets $8.944M $8.611M $5.292M
Total Assets $142.4M $158.7M $164.5M
YoY Change -6.81% -3.49% 91.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.770M $2.466M $2.987M
YoY Change -33.35% -17.44% 113.36%
Accrued Expenses $8.500M $8.300M $4.600M
YoY Change 49.12% 80.43% -17.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.27M $10.74M $7.598M
YoY Change 14.22% 41.35% 7.01%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.300M $1.400M $149.0K
YoY Change 263.13% 839.6% 49.0%
Total Long-Term Liabilities $1.300M $1.400M $149.0K
YoY Change 263.13% 839.6% 49.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.27M $10.74M $7.598M
Total Long-Term Liabilities $1.300M $1.400M $149.0K
Total Liabilities $12.52M $12.17M $7.747M
YoY Change 22.5% 57.03% 9.11%
SHAREHOLDERS EQUITY
Retained Earnings -$227.5M -$208.2M -$129.4M
YoY Change 54.45% 60.94%
Common Stock $36.00K $36.00K $27.00K
YoY Change 33.33% 33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $129.9M $146.6M $156.7M
YoY Change
Total Liabilities & Shareholders Equity $142.4M $158.7M $164.5M
YoY Change -6.81% -3.49% 91.67%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$19.29M -$18.57M -$17.49M
YoY Change 7.64% 6.16% 76.79%
Depreciation, Depletion And Amortization $600.0K $600.0K $200.0K
YoY Change 100.0% 200.0% 100.0%
Cash From Operating Activities -$15.44M -$15.92M -$12.06M
YoY Change 23.32% 32.01% 83.56%
INVESTING ACTIVITIES
Capital Expenditures $180.0K $500.0K $760.0K
YoY Change -84.62% -34.21% -34.48%
Acquisitions
YoY Change
Other Investing Activities -$29.90M $37.78M -$52.29M
YoY Change 417.3% -172.25% 64.23%
Cash From Investing Activities -$30.07M $37.28M -$53.05M
YoY Change 332.66% -170.27% 60.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $53.90M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 100.0K 54.06M 640.0K
YoY Change 25.0% 8346.87% -3300.0%
NET CHANGE
Cash From Operating Activities -15.44M -15.92M -12.06M
Cash From Investing Activities -30.07M 37.28M -53.05M
Cash From Financing Activities 100.0K 54.06M 640.0K
Net Change In Cash -45.41M 75.42M -64.47M
YoY Change 134.19% -216.98% 62.84%
FREE CASH FLOW
Cash From Operating Activities -$15.44M -$15.92M -$12.06M
Capital Expenditures $180.0K $500.0K $760.0K
Free Cash Flow -$15.62M -$16.42M -$12.82M
YoY Change 14.1% 28.08% 65.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
439000 USD
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001544227
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35561179 shares
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
OvaScience, Inc.
CY2016Q2 ovas Allocated Share Based Compensation Expense Reversed
AllocatedShareBasedCompensationExpenseReversed
1300000 USD
ovas Allocated Share Based Compensation Expense Reversed
AllocatedShareBasedCompensationExpenseReversed
2100000 USD
CY2015Q1 ovas Number Of Shares Issued Upon Full Exercise Of Options Granted To Underwriters
NumberOfSharesIssuedUponFullExerciseOfOptionsGrantedToUnderwriters
345000 shares
CY2016Q2 ovas Number Of Shares Issued Upon Full Exercise Of Options Granted To Underwriters
NumberOfSharesIssuedUponFullExerciseOfOptionsGrantedToUnderwriters
1072500 shares
CY2016Q2 ovas Numberof Treatments
NumberofTreatments
1 treatment
CY2013Q4 ovas Ownership Control Percentage With Disputes Resolved Through Arbitration
OwnershipControlPercentageWithDisputesResolvedThroughArbitration
0.5
CY2016Q2 ovas Potential Treatments In Development
PotentialTreatmentsInDevelopment
2 treatment
ovas Proceeds From Issuance Of Common Stock From Share Based Compensation Plan Net Of Tax
ProceedsFromIssuanceOfCommonStockFromShareBasedCompensationPlanNetOfTax
1365000 USD
ovas Proceeds From Issuance Of Common Stock From Share Based Compensation Plan Net Of Tax
ProceedsFromIssuanceOfCommonStockFromShareBasedCompensationPlanNetOfTax
111000 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3352000 USD
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2466000 USD
CY2015Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
7891000 USD
CY2016Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
8274000 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2420000 USD
CY2016Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3454000 USD
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-170000 USD
CY2016Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
9000 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
294910000 USD
CY2016Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
354755000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
440000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
498000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4856000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5598000 shares
CY2015Q4 us-gaap Assets
Assets
138613000 USD
CY2016Q2 us-gaap Assets
Assets
158722000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
129861000 USD
CY2016Q2 us-gaap Assets Current
AssetsCurrent
150111000 USD
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
126662000 USD
CY2016Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
147653000 USD
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2016Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
19000 USD
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
170000 USD
CY2016Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
10000 USD
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
126832000 USD
CY2016Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
147644000 USD
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
81400000 USD
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
10800000 USD
CY2016Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
6600000 USD
CY2015Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
43 security
us-gaap Cost Of Revenue
CostOfRevenue
2409000 USD
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
520000 USD
CY2016Q2 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
6 security
CY2016Q2 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
11 security
CY2016Q2 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
5 security
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6414000 USD
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70238000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43224000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95894000 USD
CY2016Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
147700000 USD
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27296747 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35560346 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27296747 shares
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35560346 shares
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
27000 USD
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
36000 USD
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17583000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34764000 USD
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18552000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40147000 USD
CY2015Q2 us-gaap Cost Of Revenue
CostOfRevenue
116000 USD
us-gaap Cost Of Revenue
CostOfRevenue
151000 USD
CY2016Q2 us-gaap Cost Of Revenue
CostOfRevenue
1233000 USD
CY2016Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1425000 USD
CY2015Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
200000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
410000 USD
CY2016Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
600000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1067000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1100000 USD
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.29
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.41
CY2013Q4 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
1500000 USD
CY2013Q4 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.5
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17490000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34696000 USD
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18518000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40201000 USD
CY2015Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-389000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-860000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11243000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
54060000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35159000 USD
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
10740000 USD
CY2016Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-416000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-807000 USD
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
50000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
125000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
388000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-921000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2778000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1208000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1787000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-544000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
439000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-197000 USD
CY2015Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
101000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
145000 USD
CY2016Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
161000 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
335000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
77000 USD
CY2015Q4 us-gaap Liabilities
Liabilities
11763000 USD
CY2016Q2 us-gaap Liabilities
Liabilities
12165000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
138613000 USD
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
158722000 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
63824000 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
52670000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
125428000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29939000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26445000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31329000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-17490000 USD
us-gaap Net Income Loss
NetIncomeLoss
-34696000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-18568000 USD
us-gaap Net Income Loss
NetIncomeLoss
-40326000 USD
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
17204000 USD
us-gaap Operating Expenses
OperatingExpenses
34032000 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
18430000 USD
us-gaap Operating Expenses
OperatingExpenses
40015000 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17174000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-33987000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18241000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-39680000 USD
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
23000 USD
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
35413000 USD
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
3117000 USD
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-93000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-68000 USD
CY2016Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
16000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
179000 USD
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-28000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000 USD
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-22000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-49000 USD
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
2300000 USD
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
1500000 USD
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
1500000 USD
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
750000 USD
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
800000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1148000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
868000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
68918000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
27142000 USD
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3002000 USD
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2458000 USD
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
124100000 USD
CY2016Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
53900000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
124063000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
53949000 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
33729000 USD
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
23089000 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10733000 USD
CY2016Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11603000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8313000 USD
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8149000 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4021000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9768000 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5987000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11942000 USD
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
197000 USD
CY2016Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0 USD
CY2016Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
439000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-167917000 USD
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-208243000 USD
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30036000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28668000 shares
CY2015Q2 us-gaap Revenues
Revenues
30000 USD
us-gaap Revenues
Revenues
45000 USD
CY2016Q2 us-gaap Revenues
Revenues
189000 USD
us-gaap Revenues
Revenues
335000 USD
CY2015Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13067000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24113000 USD
CY2016Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11210000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
25664000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
10718000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
5717000 USD
CY2016Q2 us-gaap Share Price
SharePrice
7
CY2015Q1 us-gaap Share Price
SharePrice
50
CY2015Q4 us-gaap Short Term Investments
ShortTermInvestments
83438000 USD
CY2016Q2 us-gaap Short Term Investments
ShortTermInvestments
51759000 USD
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2645000 shares
CY2016Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8222500 shares
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
126850000 USD
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
146557000 USD
us-gaap Variable Interest Entity Ownership Percentage
VariableInterestEntityOwnershipPercentage
0.5
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27198000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26894000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements are presented in conformity with U.S. generally accepted accounting principles, which require management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from such estimates.</font></div></div>

Files In Submission

Name View Source Status
0001544227-16-000013-index-headers.html Edgar Link pending
0001544227-16-000013-index.html Edgar Link pending
0001544227-16-000013.txt Edgar Link pending
0001544227-16-000013-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ovas-20160630.xml Edgar Link completed
ovas-20160630.xsd Edgar Link pending
ovas-20160630x10q.htm Edgar Link pending
ovas-20160630xex311.htm Edgar Link pending
ovas-20160630xex312.htm Edgar Link pending
ovas-20160630xex321.htm Edgar Link pending
ovas-20160630xex322.htm Edgar Link pending
ovas-20160630_cal.xml Edgar Link unprocessable
ovas-20160630_def.xml Edgar Link unprocessable
ovas-20160630_lab.xml Edgar Link unprocessable
ovas-20160630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending